Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olopatadine 0.2% once daily versus olopatadine 0.1% twice daily for allergic conjunctivitis
2016-004317-27Phase 3
- Sponsor
- Alcon Inc.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olopatadine in allergic conjunctivitis (AC) (2 arms), sponsored by Alcon Inc. Primary endpoint: Change from baseline in worst ocular itching score during the prior 24 hours at Day 14.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2016-004317-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004317-27.